We are leaders in synthetic rescue, an approach that decodes the complexity of genetic networks to reveal new ways to treat diseases. Decades of research from the laboratory of synthetic lethality pioneer Professor Steve Jackson inform our platform which is already delivering world-first, validated targets and a pipeline that offers new hope for people suffering with devastating genetic diseases. We have established a multi-target discovery alliance with GSK, which co-funded our Series A along with Ahren Innovation Capital.
Location: United Kingdom, England, Cambridge
Employees: 11-50
Total raised: $232.6M
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | Ahren Inno... | ahreninnov... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.12.2020 | Series A | $232.6M | - |
Mentions in press and media 3
| Date | Title | Description |
| 25.10.2022 | Proteros and Adrestia initiate multi-target partnership to discover first-in-class drugs for intractable genetic diseases | Proteros selected by Adrestia for its cutting-edge structure-based drug discovery engine Proteros to support Adrestia in the discovery of first-in-class drugs for intractable genetic diseases Signals new phase for Adrestia’s portfolio of va... |
| 25.10.2022 | Proteros and Adrestia initiate multi-target partnership to discover first-in-class drugs for intractable genetic diseases | Proteros selected by Adrestia for its cutting-edge structure-based drug discovery engine Proteros to support Adrestia in the discovery of first-in-class drugs for intractable genetic diseases Signals new phase for Adrestia’s portfolio of va... |
| 03.03.2022 | Adrestia Appoints Robert Johnson as Chief Executive Officer | Genetic medicine executive brings deep sector expertise to synthetic rescue leader Pioneering platform charting world-first druggable target opportunities for diseases with a genetic component Adrestia building a synthetic rescue ‘atlas’ of... |